share_log

明德生物(002932.SZ)：三季度常规业务发展状况良好，订单稳定

Matilda Biotech (002932.SZ): Regular business development in the third quarter was good, and orders were stable

Gelonghui Finance ·  08/28 10:27

Gelonghui August 28th 丨Some investors asked Matilda Biotech (002932.SZ), “How was the company's regular business in the third quarter? Is the order stable?”

Mingde Biotech replied that the company's regular business development in the third quarter was good and orders were stable!

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write first comment